

Haesuk Park

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8760358/publications.pdf>

Version: 2024-02-01

72
papers

1,509
citations

394421

19
h-index

345221

36
g-index

73
all docs

73
docs citations

73
times ranked

2499
citing authors

#	ARTICLE	IF	CITATIONS
1	Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines. <i>European Journal of Pediatrics</i> , 2022, 181, 841-845.	2.7	0
2	Machine learning algorithms for predicting direct-acting antiviral treatment failure in chronic hepatitis C: An HCV-TARGET analysis. <i>Hepatology</i> , 2022, 76, 483-491.	7.3	16
3	Dosing profiles of concurrent opioid and benzodiazepine use associated with overdose risk among US Medicare beneficiaries: group-based multi-trajectory models. <i>Addiction</i> , 2022, 117, 1982-1997.	3.3	6
4	Comparison of effectiveness and safety for low versus full dose of apixaban during extended phase oral anticoagulation in patients with venous thromboembolism. <i>Journal of Internal Medicine</i> , 2022, , .	6.0	5
5	A National Catalog of Mapped Short-Form Six-Dimension Utility Scores for Chronic Conditions in the United States From 2010 to 2015. <i>Value in Health</i> , 2022, , .	0.3	1
6	Trends in the Management of Headache Disorders in US Emergency Departments: Analysis of 2007-2018 National Hospital Ambulatory Medical Care Survey Data. <i>Journal of Clinical Medicine</i> , 2022, 11, 1401.	2.4	6
7	Trends in Sexually Transmitted Infections in United States Ambulatory Care Clinics from 2005-2016. <i>Journal of Clinical Medicine</i> , 2022, 11, 71.	2.4	4
8	Effectiveness and safety of extended oral anticoagulant therapy in patients with venous thromboembolism: a retrospective cohort study. <i>Clinical Pharmacology and Therapeutics</i> , 2022, , .	4.7	5
9	Norepinephrine reuptake inhibitors and risk of antihypertensive treatment intensification and major adverse cardiovascular events in patients with stable hypertension and depression. <i>Pharmacotherapy</i> , 2022, , .	2.6	3
10	Risk of Obstructive Sleep Apnea in Adults with Resistant Hypertension. , 2022, 1, 26-32.		1
11	Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 851-860.	4.5	5
12	Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C. <i>Hepatology Communications</i> , 2021, 5, 203-216.	4.3	14
13	Calibration of Chronic Lung Disease Severity as a Risk Factor for Respiratory Syncytial Virus Hospitalization. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 317-325.	1.3	2
14	Non-steroidal anti-inflammatory drug-associated acute kidney injury: does short-term NSAID use pose a risk in hospitalized patients?. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1409-1417.	1.9	8
15	Resource Over-Utilization in Hospitalized Patients With Uncomplicated Skin and Soft Tissue Infections. <i>Journal of Pharmacy Practice</i> , 2021, , 089719002110002.	1.0	0
16	Changes in Schedule II oral opioid volume dispensed in a private health plan following Florida's Acute Pain Opioid Restriction Law. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 779-784.	0.9	6
17	Effectiveness of sacubitril/valsartan versus aldosterone antagonists in heart failure with reduced ejection fraction: A retrospective cohort study. <i>Pharmacotherapy</i> , 2021, 41, 710-721.	2.6	1
18	Health-Related Quality of Life and Health Utilities of Mild, Moderate, and Severe Asthma: Evidence from the Medical Expenditure Panel Survey. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 929-941.	3.4	9

#	ARTICLE	IF	CITATIONS
19	Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States. <i>JCO Oncology Practice</i> , 2021, , OP.21.00140.	2.9	6
20	The Impact of Direct-Acting Antiviral Therapy on End-Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders. <i>Hepatology</i> , 2021, 74, 566-581.	7.3	9
21	US national trends in bariatric surgery: A decade of study. <i>Surgery</i> , 2021, 170, 13-17.	1.9	75
22	The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 873-881.	0.9	4
23	Self-reported hepatitis C(HCV) testing among people living with human immunodeficiency virus (PLWH). <i>Heliyon</i> , 2021, 7, e07727.	3.2	1
24	Cascade of Hepatitis C Virus Care Among Patients With Substance Use Disorders. <i>American Journal of Preventive Medicine</i> , 2021, 61, 576-584.	3.0	7
25	Surveillance of patients with cirrhosis remains suboptimal in the United States. <i>Journal of Hepatology</i> , 2021, 75, 856-864.	3.7	20
26	Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1388-1402.	0.9	2
27	Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019. <i>JAMA Network Open</i> , 2021, 4, e2133474.	5.9	6
28	Adherence Trajectories of Extended Direct-Acting Oral Anticoagulants and Risk of Recurrent Venous Thromboembolism and Major Bleeding: A Retrospective Cohort Study. <i>Blood</i> , 2021, 138, 4059-4059.	1.4	2
29	Comparative Effectiveness and Safety of Extended Anticoagulant Therapy Among Medicare Beneficiaries with Venous Thromboembolism. <i>Blood</i> , 2021, 138, 178-178.	1.4	1
30	A Nationwide Study of Inpatient Admissions, Mortality, and Costs for Patients with Cirrhosis from 2005 to 2015 in the USA. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1520-1528.	2.3	25
31	Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 705-710.	4.4	3
32	Usability of encounter data for Medicaid comprehensive managed care vs traditional Medicaid fee-for-service claims among pregnant women. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 30-38.	1.9	2
33	Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis. <i>Clinical Therapeutics</i> , 2020, 42, e161-e176.	2.5	2
34	Trends in HIV Preexposure Prophylaxis Prescribing in the United States, 2012-2018. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 395.	7.4	21
35	<p></p>Medical Costs and Productivity Loss Due to Mild, Moderate, and Severe Asthma in the United States</p>. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 545-555.	3.4	21
36	Out-of-Pocket Payment for Ambulatory Blood Pressure Monitoring Among Commercially Insured in the United States. <i>American Journal of Hypertension</i> , 2020, 33, 999-1002.	2.0	3

#	ARTICLE	IF	CITATIONS
37	Trends in ambulatory blood pressure monitoring use for confirmation or monitoring of hypertension and resistant hypertension among the commercially insured in the U.S., 2008â€“2017. <i>International Journal of Cardiology: Hypertension</i> , 2020, 6, 100033.	2.2	9
38	Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 851-866.	1.9	21
39	Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 188-195.	1.0	13
40	Reimbursement of ambulatory blood pressure monitoring in the US commercial insurance marketplace. <i>Journal of Clinical Hypertension</i> , 2020, 22, 6-15.	2.0	10
41	Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3159-3174.	2.3	3
42	Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma. <i>JAMA Network Open</i> , 2020, 3, e201611.	5.9	70
43	Impact of hepatitis C virus treatment on the risk of nonâ€“hepatic cancers among hepatitis C virusâ€“infected patients in the US. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1592-1602.	3.7	12
44	Cardiovascular outcomes of sodium glucose cotransporterâ€“2 inhibitors in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 28-36.	4.4	58
45	Comparative Effectiveness and Safety of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome: A Retrospective Cohort Analysis. <i>Pharmacotherapy</i> , 2019, 39, 912-920.	2.6	9
46	Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensityâ€“matched cohort study. <i>Journal of Internal Medicine</i> , 2019, 286, 711-722.	6.0	51
47	The association between proton pump inhibitor use and the risk of tuberculosis: A caseâ€“control study. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 830-839.	1.9	2
48	Can apixaban prevent venous thromboembolism better than rivaroxaban? â€“ Authors' reply. <i>Lancet Haematology</i> , the, 2019, 6, e181-e182.	4.6	0
49	Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. <i>Lancet Haematology</i> , the, 2019, 6, e20-e28.	4.6	65
50	Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA. <i>Digestive Diseases and Sciences</i> , 2019, 64, 698-707.	2.3	26
51	Impact of Allâ€“Oral Directâ€“Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States. <i>Hepatology</i> , 2019, 69, 1032-1045.	7.3	46
52	Trends in Readmission Rates, Hospital Charges, and Mortality for Patients With Chronic Obstructive Pulmonary Disease (COPD) in Florida From 2009 to 2014. <i>Clinical Therapeutics</i> , 2018, 40, 613-626.e1.	2.5	15
53	Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD. <i>Hepatology</i> , 2018, 67, 492-504.	7.3	68
54	Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006â€“2015). <i>BMC Nephrology</i> , 2018, 19, 318.	1.8	24

#	ARTICLE	IF	CITATIONS
55	Higher mortality and hospital charges in patients with cirrhosis and acute respiratory illness: a population-based study. <i>Scientific Reports</i> , 2018, 8, 9969.	3.3	7
56	Economic and clinical burden of viral hepatitis in California: A population-based study with longitudinal analysis. <i>PLoS ONE</i> , 2018, 13, e0196452.	2.5	10
57	Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists. <i>Cardiovascular Diabetology</i> , 2018, 17, 102.	6.8	17
58	Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study. <i>Journal of Affective Disorders</i> , 2018, 238, 542-546.	4.1	18
59	The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?. <i>Liver International</i> , 2017, 37, 662-668.	3.9	16
60	Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States. <i>Medicine (United States)</i> , 2016, 95, e5048.	1.0	32
61	Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. <i>Gastroenterology</i> , 2016, 150, 1599-1608.	1.3	315
62	Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. <i>American Journal of Managed Care</i> , 2016, 22, SP205-11.	1.1	31
63	Managing Oral Phosphate Binder Medication Expenditures Within the Medicare Bundled End-Stage Renal Disease Prospective Payment System: Economic Implications for Large U.S. Dialysis Organizations. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 507-514.	0.9	4
64	Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 956-964.	0.9	4
65	Direct Medical Costs and Utilization of Health Care Services to Treat Pneumonia in the United States: An Analysis of the 2007-2011 Medical Expenditure Panel Survey. <i>Clinical Therapeutics</i> , 2015, 37, 1466-1476.e1.	2.5	29
66	Adherence and Persistence to Prescribed Medication Therapy Among Medicare Part D Beneficiaries on Dialysis: Comparisons of Benefit Type and Benefit Phase. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 862-876.	2.2	32
67	Scales of Smoking-Related Self-Efficacy, Beliefs, and Intention: Assessing Measurement Invariance among Intermittent and Daily High School Smokers. <i>American Journal of Health Promotion</i> , 2014, 28, 310-315.	1.7	8
68	Assessing the Invariance of Smoking-Related Self-Efficacy, Beliefs, and Intention Among High School Current Smokers. <i>Substance Use and Misuse</i> , 2013, 48, 477-483.	1.4	3
69	Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1453-1469.	1.9	86
70	Cost-Effectiveness of Expanded Newborn Screening in Texas. <i>Value in Health</i> , 2012, 15, 613-621.	0.3	27
71	Evaluation of Health Care Costs and Utilization Patterns for Patients With Gout. <i>Clinical Therapeutics</i> , 2012, 34, 640-652.	2.5	39
72	Cost-Effectiveness of Lanthanum Carbonate versus Sevelamer Hydrochloride for the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease: A US Payer Perspective. <i>Value in Health</i> , 2011, 14, 1002-1009.	0.3	24